Dr. Eyre on Resistance to BTK Inhibition in MCL

Rebooting the BTK Inhibitor Sequence in MCLПодробнее

Dr. Eyre on BTK Inhibitors in Combination With Venetoclax for MCLПодробнее

Watch Drs. Eyre and Shah discuss #Lymphoma - https://bit.ly/3R0nseNПодробнее

Dr. Ruan Discusses BTK Inhibitors in MCLПодробнее

Dr. Hill on Resistance to BTK Inhibition in CLLПодробнее

Dr. Rule on the Role of BTK Inhibitors in MCLПодробнее

Resistance to BTK Inhibitors in B-Cell MalignanciesПодробнее

Dr. Shah on Overcoming Resistance to BTK Inhibitors in MCLПодробнее

Selecting between BTK inhibitors in MCL & addressing resistance to these agentsПодробнее

Dr. Smith on Safety Profiles of BTK Inhibitors in MCLПодробнее

Dr. Leslie on the Role of BTK Inhibitors in Relapsed/Refractory MCLПодробнее

Novel therapies for patients with MCL after failed response to BTK inhibitorsПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

Dr. Eyre Discusses Venetoclax Monotherapy in MCLПодробнее

Prognostic markers in MCL and the value of CAR-T therapy in treating high-risk diseaseПодробнее

Dr. Patel on Differences Between BTK Inhibitors in MCLПодробнее

Selecting BTK inhibitors for patients with MCLПодробнее

BTK inhibitors for R/R MCL: current uses and insights from the ViPOR studyПодробнее

Dr Koff on the Role of Covalent BTK Inhibitors and Pirtobrutinib in MCLПодробнее